Imaging of prostate cancer

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 259-264

  Oehr, Peter ^a   Bouchelouche, Kirsten ^b,c  

^a UNIVERSITY OF BONN   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Elastography; Magnetic resonance imaging; Magnetic resonance spectroscopy; Positron emission tomography; Prostate cancer; Transrectal ultrasonography

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BONE SCINTISCANNING; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; ELASTOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; TUMOR LOCALIZATION;

HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 34247141482     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280ad439b     Document Type: Review

References (31)

1. Pelzer A, Bektic J, Berger AP, et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005; 173:1926-1929.
2. Halpern EJ, Ramey JR, Strup SE, et al. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005; 104:2373-2383.
3. Yi A, Kim JK, Park SH, et al. Contrast-enhanced sonography for prostate cancer detection in patients with indeterminate clinical findings. AJR Am J Roentgenol 2006; 186:1431-1435. This study confirms that the sensitivity by biopsy is greater for contrast enhanced sonography than gray scale and color Doppler sonography.
4. Drudi FM, Giovagnorio F, Carbone A, et al. Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy: comparison with MRI. Ultraschall Med 2006; 27:146-151.
5. Miyanaga N, Akaza H, Yamakawa M, et al. Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. Int J Urol 2006; 13:1514-1518.
6. Konig K, Scheipers U, Pesavento A, et al. Initial experiences with real-time elastography guided biopsies of the prostate. J Urol 2005; 174:115-117.
7. Curiel L, Souchon R, Rouviere O, et al. Elastography for the follow-up of high-intensity focused ultrasound prostate cancer treatment: initial comparison with MRI. Ultrasound Med Biol 2005; 31:1461-1468.
8. Wetter A, Engl TA, Nadjmabadi D, et al. Combined MRI and MR spectroscopy of the prostate before radical prostatectomy. AJR Am J Roentgenol 2006; 187:724-730.
9. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241:449-458. Showed significantly that contrast-enhanced MRI and three-dimensional MRS imaging improved accuracy in prostate cancer localization compared with use of T2-weighted MRI alone.
10. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy: initial experience. Radiology 2005; 236:545-553.
11. Barnes AS, Haker SJ, Mulkern RV, et al. Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology 2005; 66:1319.
12. Wang L, Hricak H, Kattan MW, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007; 242:182-188. This study shows that the addition of MRI contributes significant value to the Kattan nomogram for predicting SVI.
13. 11C-choline PET/CT to PSA at equal sensitivity.
14. 11C-choline PET/CT in differentiation between benign and malign processes.
15. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46:1642-1649.
16. 11C-choline PET/CT may localize tumors inside prostate. For assessment of extraprostatic extension, however, sensitivity was low compared with MRI.
17. Yamaguchi T, Lee J, Uemura H, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005; 32:742-748.
18. 18F-fluorocholine PET malignant areas.
19. Hacker A, Jeschke S, Leeb K, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176:2014-2018.
20. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235:623-628.
21. 18F-fluorocholine PET may have a role in the management of patients suspected of having recurrence, especially in patients with PSA above 4 ng/ml.
22. 18F-fluorocholine PET in restaging of patients with recurrence.
23. Albrecht S, Buchegger F, Soloviev D, et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34:185-196.
24. Sandblom G, Sorensen J, Lundin N, et al. Positron emission tomography with C11- acetatefortumordetectionandlocalizationinpatientswithprostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67:996-1000.
25. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006; 24:2513-2519.
26. Warren KS, Chodak GW, See WA, et al. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? J Urol 2006; 176:70-73. In this large report with 8100 men, the incidence of positive bone scans was correlated with PSA. The conclusion was that bone scans can be eliminated in follow-up of patients with early prostate cancer after standard treatment when PSA is less than 5 ng/ml. The level can be increased to 20 ng/ml with caution.
27. Salonia A, Gallina A, Camerota TC, et al. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. Urology 2006; 68:362-366.
28. 18F-fluoride PET/CT for detection of bone metastases in patients with high-risk prostate cancer.
29. Gutman F, Aflalo-Hazan V, Kerrou K, et al. 18F-Choline PET/CT for initial staging of advanced prostate cancer. AJR Am J Roentgenol 2006; 187:W618-W621.
30. Toth G, Lengyel Z, Balkay L, et al. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005; 173:66-69.
31. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32:344-350.